Supplementary Figure S4

A

	GI50 (μM)								
	D567N	D567Y	G607C	C620R	D631Y	D631_L633 delinsE	D632_L633 del	C634R	M918T
Selpercatinib	0.5753	0.004717	0.06607	0.197	0.05701	0.03366	0.05096	0.04129	0.02389
Pralsetinib	0.1422	0.003565	0.06542	0.07528	0.03442	0.01089	0.01259	0.08752	0.06378

B



Supplementary Figure S4. The oncogenic/tumorigenic activity of RET-CaLM mutants was suppressed by RET-TKIs

A, GI50 values of selpercatinib and pralsetinib for Ba/F3 cells expressing RET mutants. Data are expressed as the mean value of six replicates. GI50, 50% growth inhibitory concentration. **B,** Tumors of RET mutant-expressing NIH3T3 cells after treatment with vehicle (top), selpercatinib (middle), or pralsetinib (bottom). Tumors for D567Y (left) and C634R (right) mutants were dissected from subjects after treatment completion.